BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
Gastroesophageal Junction Cancer
Advertisement
BeOne Wins FDA Approval for TEVIMBRA HER2+ GEA Regimen
SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials
CHENGDU, China, July 27, 2026 Kelun-Biotech has announced that the Center for Drug Evaluation (CDE) of China’s National Medical...
AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough
CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Advertisements
Ono’s ONO-4578 Improves Progression-Free Survival in Gastric Cancer Phase 2 Study
OSAKA, Japan, June 2, 2026 Ono Pharmaceutical announced positive Phase 2 clinical trial results for ONO-4578, its investigational oral...
Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
Advertisement
